Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
54 studies found for:    Holden Comprehensive Cancer Center | Open Studies
Show Display Options
Rank Status Study
1 Not yet recruiting A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme
Condition: Glioblastoma Multiforme
Interventions: Drug: Temozolomide;   Radiation: radiation therapy;   Drug: Ascorbic Acid
2 Recruiting Ketogenic Diet Phase 1 for Head & Neck Cancer
Condition: Head and Neck Neoplasms
Intervention: Dietary Supplement: Ketogenic diet
3 Recruiting Pharmacological Ascorbate for Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Ascorbic Acid
4 Recruiting Dose Escalation Phase I/II Study of Lovastatin With High-Dose Cytarabine for Refractory or Relapsed AML
Condition: Acute Myeloid Leukemia
Intervention: Drug: Lovastatin and Cytarabine
5 Recruiting Gemcitabine, Ascorbate, Radiation Therapy for Pancreatic Cancer, Phase I
Condition: Pancreatic Neoplasms
Interventions: Drug: Ascorbate;   Drug: Gemcitabine;   Radiation: Radiation therapy
6 Not yet recruiting Decitabine and Gemcitabine for Pancreatic Cancer and Sarcoma
Conditions: Pancreatic Ductal Adenocarcinoma;   Sarcoma
Interventions: Drug: Decitabine;   Drug: Gemcitabine
7 Recruiting Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma
Conditions: Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage II Grade 1 Contiguous Follicular Lymphoma;   Stage II Grade 1 Non-Contiguous Follicular Lymphoma;   Stage II Grade 2 Contiguous Follicular Lymphoma;   Stage II Grade 2 Non-Contiguous Follicular Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Biological: Rituximab;   Radiation: Yttrium Y-90 Ibritumomab Tiuxetan
8 Not yet recruiting A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer
Conditions: Pancreatic Neoplasms;   Cancer of Pancreas;   Cancer of the Pancreas;   Neoplasms, Pancreatic;   Pancreas Cancer;   Pancreas Neoplasms;   Adenocarcinoma
Interventions: Drug: Gemcitabine;   Drug: nab-paclitaxel;   Drug: Ascorbic Acid
9 Not yet recruiting A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC
Conditions: Carcinoma, Non-Small-Cell Lung;   Non-Small Cell Lung Cancer;   Nonsmall Cell Lung Cancer;   Non-Small-Cell Lung Carcinoma;   NSCLC
Interventions: Drug: Radiation Therapy;   Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Ascorbic Acid
10 Not yet recruiting Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer
Conditions: Early-Stage Breast Carcinoma;   Estrogen Receptor Negative;   Estrogen Receptor Positive;   Grade 2 Invasive Breast Carcinoma;   Grade 3 Invasive Breast Carcinoma;   HER2/Neu Negative;   HER2/Neu Positive
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Retinoid 9cUAB30;   Procedure: Therapeutic Conventional Surgery
11 Recruiting Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency
Conditions: Aggressive Non-Hodgkin Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-Cell Lymphoma;   Chronic Lymphocytic Leukemia;   Diffuse Large B-Cell Lymphoma;   Enteropathy-Associated T-Cell Lymphoma;   Hepatosplenic T-Cell Lymphoma;   Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Mediastinal (Thymic) Large B-Cell Lymphoma;   Nasal Type Extranodal NK/T-Cell Lymphoma;   Peripheral T-Cell Lymphoma, Not Otherwise Specified;   Primary Cutaneous Anaplastic Large Cell Lymphoma;   Refractory Anaplastic Large Cell Lymphoma;   Small Lymphocytic Lymphoma;   Subcutaneous Panniculitis-Like T-Cell Lymphoma
Interventions: Dietary Supplement: Cholecalciferol;   Other: Laboratory Biomarker Analysis
12 Recruiting Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY)
Conditions: Infection;   Bone Neoplasms
Interventions: Drug: 24-Hour Prophylactic Cefazolin* Antibiotic Regimen;   Drug: 5-Days Prophylactic Cefazolin* Antibiotic Regimen
13 Recruiting A Phase 1-2 Multi-Center Study Evaluating KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1)
Conditions: Refractory Diffuse Large B Cell Lymphoma;   Refractory Primary Mediastinal B Cell Lymphoma;   Refractory Transformed Follicular Lymphoma;   Relapsed/Refractory Transplant Ineligible Diffuse Large B Cell Lymphoma;   Relapsed/Refractory Transplant Ineligible Primary Mediastinal B Cell Lymphoma;   Relapsed/Refractory Transplant Ineligible Transformed Follicular Lymphoma
Intervention: Biological: KTE-C19
14 Recruiting Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Conditions: Large Cell Lung Carcinoma;   Lung Adenocarcinoma;   Stage IB Non-Small Cell Lung Carcinoma;   Stage IB Squamous Cell Lung Carcinoma;   Stage IIA Non-Small Cell Lung Carcinoma;   Stage IIA Squamous Cell Lung Carcinoma;   Stage IIB Non-Small Cell Lung Carcinoma;   Stage IIB Squamous Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIA Squamous Cell Lung Carcinoma
Interventions: Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis
15 Recruiting Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma
Conditions: Lymphoma;   Lymphoproliferative Disorder
Interventions: Other: biologic sample preservation procedure;   Other: informational intervention
16 Recruiting Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma
Condition: Sarcoma
Intervention: Other: biologic sample preservation procedure
17 Recruiting Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Conditions: Adult B Acute Lymphoblastic Leukemia;   Adult T Acute Lymphoblastic Leukemia;   Childhood B Acute Lymphoblastic Leukemia;   Childhood T Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis
18 Recruiting R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma
Conditions: Diffuse Large B-Cell Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Transformed Recurrent Non-Hodgkin Lymphoma
Interventions: Drug: Carboplatin;   Drug: Etoposide;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Biological: Rituximab
19 Recruiting Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
Conditions: B Acute Lymphoblastic Leukemia;   Bone Necrosis;   Central Nervous System Leukemia;   Cognitive Side Effects of Cancer Therapy;   Neurotoxicity Syndrome;   Pain;   Testicular Leukemia;   Therapy-Related Toxicity;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: Clofarabine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dasatinib;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Hydrocortisone Sodium Succinate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Radiation: Radiation Therapy;   Drug: Thioguanine;   Drug: Vincristine Sulfate
20 Recruiting Brentuximab Vedotin and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Hodgkin Lymphoma
Conditions: Classical Hodgkin Lymphoma;   Stage IIB Hodgkin Lymphoma;   Stage IIIB Hodgkin Lymphoma;   Stage IVA Hodgkin Lymphoma;   Stage IVB Hodgkin Lymphoma
Interventions: Biological: Bleomycin Sulfate;   Drug: Brentuximab Vedotin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Prednisone;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Vincristine Sulfate

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.